Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank - 2Mexico says a third of 130,000 missing people might be alive, fueling criticism from families
- 3How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- 4Brazil's ex-president Bolsonaro operated on for hernia
- 56 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- The Secret Destinations Amex Says Will Be More Popular Than Bali by 2026
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- Famous Restroom Beautifying Styles For 2024
- Obamacare enrollment declines as US subsidies expire
- The Starbucks for Life game is back, along with your chance to win a 'Bearista' cold cup. Here's how to get your paws on one.
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- Israel has clear objectives south of Litani River, but will face difficult choices further north
- As world leaders enter climate talks, people in poverty have the most at stake
